L-Carnitine as an Adjuvant Treatment in Acute Phosphide Poisoning (LC)

Status Completed

Clinical Trial Summary

The aim of this study was to evaluate efficacy and safety of Alpha Lipoic Acid(ALA) as an adjuvant in the management of patients with acute phosphide poisoning.

Clinical Trial Description

The study was carried out following approval of the research ethical committee of Tanta Faculty of Medicine on patients admitted to The Poison Control Unit (Emergency Hospitals, Tanta and Mansoura Universities) with acute phosphide poisoning in the period from January 2016 to January 2018. A written informed consent was taken from each patient or his/her guardians (if the patient was unable to participate in the consent process). Confidentiality of the data was maintained by making code numbers for each patient. The investigators planned to conduct a randomized clinical trial to evaluate efficacy and safety of LC as an adjuvant in treatment of patients with acute phosphide poisoning. Fifty patients was randomized to LC or a non LC in a 1:1 ratio (25 patients in each group). LC was given IV, as a dose of 1 g/8 hours. Patients was monitored and a detailed documentation of any adverse effect due to LC therapy was recorded.

This intervention represented an added treatment to the existing standard of care. All patients will continue to receive standard treatment, which was determined by the attending physician who maintained clinical responsibility for all patients. It consisted of patient resuscitation, gastric decontamination (with sodium bicarbonate, and activated charcoal [1 g/Kg, orally] in the first 6 hours after onset of poisoning), adequate hydration and supportive treatment. All the patients was followed up until discharge or death. All patients was subjected to:

I. History. II. Clinical examination. III. Laboratory investigations: At admission and repeated before discharge. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03953248
Study type	Interventional
Source	Kafrelsheikh University
Contact
Status	Completed
Phase	Early Phase 1
Start date	January 2016
Completion date	January 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02273713` - The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION)	Phase 1/Phase 2
Terminated	`NCT00531076` - Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-small Cell Cell Lung Cancer	Phase 1
Active, not recruiting	`NCT02397434` - Adjuvant Radiotherapy After Cystectomy for Muscle Invasive Bladder Cancer	N/A
Withdrawn	`NCT03342300` - Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma	Phase 2/Phase 3
Active, not recruiting	`NCT02649491` - Using an Electronic Nose to Predict Gastrointestinal Consequences of Pelvic Radiotherapy	N/A
Active, not recruiting	`NCT03975452` - Volume De-escalation in Neoadjuvant Radiochemotherapy of Rectal Cancer	N/A
Terminated	`NCT00618917` - MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC)	Phase 1/Phase 2
Not yet recruiting	`NCT02760823` - Alpha Lipoic Acid as an Adjuvant Treatment in Acute Phosphide Poisoning	Phase 2
Completed	`NCT02864030` - PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment	Phase 4
Completed	`NCT00890448` - Case Control Study of Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure to Lapaquistat Acetate	N/A
Terminated	`NCT01760356` - Study of PD/PK/PG Relationships of Tacrolimus and Cyclosporin in Liver Transplant Patients
Recruiting	`NCT06044623` - Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients	Phase 3
Completed	`NCT01091766` - Sensitivity of ECG on Detection of Three Different Intravascular Applied Test Doses of Bupivacaine and Epinephrine	Phase 4
Completed	`NCT05277480` - Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)	Phase 2
Recruiting	`NCT03978949` - Prevention of Radiotherapy Induced Enteropathy by Probiotics (PREP)	Phase 3
Completed	`NCT03491371` - Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use	N/A
Completed	`NCT02143219` - Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer	Phase 2
Completed	`NCT02054741` - Geriatric Assessment Intervention for Reducing Toxicity in Older Patients With Advanced Cancer	N/A
Not yet recruiting	`NCT06087718` - Feasibility of the Maastro Applicator in Rectal Cancer	N/A
Terminated	`NCT02512809` - Isoflurane-induced Neuroinflammation in Children With Hydrocephalus	Phase 3